Joshua Richter, MD

A brief review of the role of transplant in patients with newly diagnosed multiple myeloma and how it can be best coupled with systemic treatment.

Comprehensive insight on mainstay induction therapy options for patients with transplant-eligible newly diagnosed multiple myeloma in the context of recent clinical studies.

Opening their discussion on the first patient case, expert panelists review the management of transplant-eligible newly diagnosed multiple myeloma.

Dr. Joshua Richter and Dr. Peter Forsberg close their discission with thoughtful advice for clinicians regarding the current and future treatment of patients with R/R MM.

Insights on supportive care measures to minimize or counter common adverse effects for patients with R/R MM taking selinexor-based therapies

Discourse centered around dosing strategies for selinexor-based therapies.

Two subject matter experts discuss keystone trials supporting the use of Selinexor in patients with R/R MM, each with unique dosing structures and different selinexor-based combinations.

Opening their discussion on relapsed/refractory multiple myeloma, Joshua Richter, MD and Peter Forsberg, MD review options for treatment sequencing, initiating treatment, and the mechanism of action for selinexor.

Drs Richter and Fanning discuss next steps and future directions in the management of patients with relapsed/refractory multiple myeloma.

Experts summarize key points from routine clinical practice on use of ixazomib, lenalidomide, and dexamethasone (IRD) in patients with relapsed/refractory multiple myeloma.

Hematologic oncologists discuss toxicities seen with ixazomib, lenalidomide, and dexamethasone (IRd) compared with lenalidomide and dexamethasone (Rd).

Two experts discuss cytogenetic profiles in patients with relapsed/refractory multiple myeloma treated with either doublet or triplet therapy.

Data review of IRD vs Rd in patients with relapsed/refractory multiple myeloma who had a prior autologous stem cell transplant or extramedullary disease.

Experts provide commentary on the subgroup analyses from real-world data on use of ixazomib, lenalidomide, and dexamethasone compared with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Suzanne Fanning, DO, and Joshua Richter, MD discuss efficacy outcomes seen in a routine clinical practice study of ixazomib, lenalidomide and dexamethasone [IRD] compared with lenalidomide and dexamethasone [Rd] in patients with relapsed/refractory multiple myeloma.

Drs Fanning and Richter review the baseline characteristics of patients included in the routine clinical practice publication of ixazomib, lenalidomide, and dexamethasone [IRD] versus lenalidomide and dexamethasone [Rd] in patients with relapsed/refractory multiple myeloma.

Multiple myeloma experts share background for discussion of the recent publication, “Survival benefit of ixazomib, lenalidomide and dexamethasone [IRD] over lenalidomide and dexamethasone [Rd] in relapsed and refractory multiple myeloma patients in routine clinical practice.”